The effect of darbepoetin alfa on patients with chronic renal disease and renal anemia (A real-world study)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057105

Enrollment

Unknown

Registered

2022-02-28

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease and renal anemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients signed informed consent file; 2. Patients diagnosed with renal anemia 3. Aged >= 18 years; 4. Patients received erythropoietin or Daepotine a.

Exclusion criteria

Exclusion criteria: 1. Allergic to Daepotine a, erythropoietin or any excipients of the product; 2. Acute coronary syndrome, stroke, thromboembolism or seizure within 3 months before screening; 3. Uncontrollable hypertension during screening; 4. Grade IV NYHA heart failure; 5. A history of malignant tumor; 6. Women who are pregnant or breastfeeding or women of childbearing potential who are not willing to use appropriate contraception; 7. Patients who are participating in or will participate in an investigational interventional study during the study.

Design outcomes

Primary

Measure	Time frame
Hemoglobin;	—

Secondary

Measure	Time frame
Serum ferritin;Ferritin;Transferring;Transferrin saturation;Total iron binding force;	—

Countries

China

Contacts

Public ContactQijun Wan

Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University

yiyuan2224@sina.com+86 13536857368

Outcome results